Access for ALL in ALS: A large-scale, inclusive, collaborative consortium to unlock the molecular and genetic mechanisms of amyotrophic lateral sclerosis
Recent progress in therapeutics for amyotrophic lateral sclerosis (ALS) has spurred development and imbued the field of ALS with hope for more breakthroughs, yet substantial scientific gaps persist. This unmet need remains a stark reminder that innovative paradigms are needed to invigorate ALS research. To move toward more informative, targeted, and personalized drug development, the […]
First Participant Enrolled in NIH-Funded Access for All in ALS Consortium
The Access for All in ALS Consortium (ALL ALS) announced the successful enrollment of the first participant. Established in the autumn of 2023 with funding from the National Institutes of Health (NIH), ALL ALS is a multi-institutional effort, and aims to disrupt the ALS clinical research landscape using open science methods to build broadly accessible resources […]
National Institutes of Health (NIH) funds New Multi-Institutional ALS Clinical Research Consortium
ALS is a complex neurodegenerative disease, but the causes remain poorly understood and there are few effective therapies available. There is an urgent need for large-scale, collaborative efforts to identify useful biofluid biomarkers that can guide researchers about its onset, progression, and response to effective therapies. To achieve these goals, the NIH has established a […]